Literature DB >> 6256319

Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.

S E Order, J L Klein, D Ettinger, P Alderson, S Siegelman, P Leichner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6256319     DOI： 10.1016/0360-3016(80)90226-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  15 in total

1.  Percolation and binding of monoclonal antibody BW494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.

Authors:  K Bosslet; H C Keweloh; P Hermentin; K H Muhrer; H H Sedlacek; G Schulz
Journal:  Br J Cancer Suppl       Date:  1990-07

Review 2.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

3.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  Med Phys       Date:  1998-01       Impact factor: 4.071

4.  Radiation protection.

Authors:  E W Spiers
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

5.  Radioimmunotechnology for cancer diagnosis and treatment.

Authors:  S Holt; B M Longenecker; A A Noujaim
Journal:  Can Med Assoc J       Date:  1983-07-01       Impact factor: 8.262

6.  Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins.

Authors:  D Goodwin; C Meares; C Diamanti; M McCall; C Lai; F Torti; M McTigue; B Martin
Journal:  Eur J Nucl Med       Date:  1984

7.  Antibody-targeted photolysis: in vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier.

Authors:  S L Rakestraw; R G Tompkins; M L Yarmush
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

8.  Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Authors:  Jay H Solanki; Thomas Tritt; Jordan B Pasternack; Julia J Kim; Calvin N Leung; Jason D Domogauer; Nicholas W Colangelo; Venkat R Narra; Roger W Howell
Journal:  Radiat Res       Date:  2017-05-25       Impact factor: 2.841

9.  Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies.

Authors:  B Delaloye; A Bischof-Delaloye; F Buchegger; V von Fliedner; J P Grob; J C Volant; J Pettavel; J P Mach
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

10.  Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations.

Authors:  J D Rodwell; V L Alvarez; C Lee; A D Lopes; J W Goers; H D King; H J Powsner; T J McKearn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.